Fisetin
FY-se-tin
IUPAC 2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one
SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=CC(=CC=C3O2)O)O)O)O
C-
31.0/100
Evidence Summary
Fisetin exemplifies the senolytic evidence gap. A 2018 preclinical study identified it as the most potent senolytic flavonoid, extending healthspan in aged mice. This generated enormous consumer interest.
However, no completed Phase 2+ RCT has demonstrated senolytic efficacy in humans. The AFFIRM trial and other ongoing studies may change this, but as of 2026, fisetin's human evidence consists of small pilot studies with biomarker endpoints only.
The senolytic field overall is the most over-hyped relative to evidence in the entire longevity space.
However, no completed Phase 2+ RCT has demonstrated senolytic efficacy in humans. The AFFIRM trial and other ongoing studies may change this, but as of 2026, fisetin's human evidence consists of small pilot studies with biomarker endpoints only.
The senolytic field overall is the most over-hyped relative to evidence in the entire longevity space.
Safety Considerations
Generally well-tolerated as a dietary flavonoid. Bioavailability is low without lipid formulation. Drug interactions possible via CYP enzyme inhibition. Pulsed dosing protocols (senolytic intent) have minimal safety data in humans. Pregnant/nursing should avoid.
Evidence Signals (0)
Known Interactions (1)
Products Containing Fisetin
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.